Benefit of selective factor inhibition.
Turpie
Alexander G G
AG
Hamilton Health Sciences-Hamilton General Hospital, Hamilton, Ontario, Canada.
Büller
Harry R
HR
D000990:Antithrombin III / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use; D013379:Substrate Specificity; D013917:Thrombin / Q000037:antagonists & inhibitors; D013923:Thromboembolism / Q000188:drug therapy*
D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D000990:Antithrombin III; D013917:Thrombin; D000077425:Fondaparinux